Menu
Close
NanoTess, co-founded by Megan Leslie, innovates wound care with NanoSALV, a catalytic gel addressing healing, inflammation, and infection. Their mission prioritizes accessibility, global expansion, and impactful healthcare.
Megan Leslie, the CEO and co-founder of NanoTess, alongside her team have made remarkable strides in healthcare innovation, particularly in the realm of wound care. Founded with a clear mission, NanoTess operates as a social enterprise, aiming not only to develop cutting-edge technologies, but also to provide affordable and accessible catalytic innovations to everyone who needs them. Their journey began with personal struggles, as many team members were directly impacted by difficulties accessing and affording healthcare, with one of the NanoTess founders even losing both parents to chronic conditions. Deeply inspired by their own struggles, they founded NanoTess, beginning with a focus on treating non-healing, chronic wounds with their product, NanoSALV Catalytic Advanced Wound Care Treatment Matrix!
NanoSALV Catalytic is an easy-to-use amorphous cellulose matrix gel containing NanoKARE™, NanoTess's proprietary composite material. Its technology facilitates three crucial processes: to promote healing, reduce inflammation, and act as a broad-spectrum antimicrobial. This combination makes it unique as it supports these three important functions in a single solution. The wound gel is designed to support the skin, all the way down to bone. Wounds are typically impacted by at least one of four main factors: injury (damage and breaches), inflammation or irritation, infection, and/or systemic conditions. NanoSALV provides meaningful support for three of these four factors including healing, inflammation, and infection when used within conjunction with standard of care.
The versatility of the NanoSALV Catalytic allows it to be used for various applications, addressing both early-stage and advanced wound care needs. For early-stage, it supports skin and minor wounds such as cuts, scrapes, and burns, helping to prevent progression into a more severe condition. In advanced wound care, it is effective in managing chronic and difficult-to-heal wounds, such as diabetic foot ulcers, pressure injuries and severe burns. It also plays an important role in post-surgical support, facilitating healing and minimising risks of infection, re-infection, ulceration and even amputation. Clinical data shows that NanoSALV Catalytic can accelerate wound healing. For example wounds expected to heal in four months can potentially heal in half the time (two months). As a result, NanoTess has significantly reduced healing time for patients, ultimately leading to both cost and time savings as well as improved quality of life.
Currently, NanoSALV is available at select pharmacies across Canada, and has been integrated into various care facilities, including Alberta Health Services (AHS) public healthcare sites, within hospitals, dermatology clinics, homecare service providers, specialty wound care clinics and long-term care sites across Canada. NanoTess is continuing to expand its adoption across different healthcare settings. Additionally, NanoTess is planning global expansion, targeting Latin America and the United States first, with a long-term vision of making advanced wound care accessible to underserved and vulnerable communities worldwide.
Looking ahead, NanoTess envisions incorporating their catalytic technology into existing products to enhance the healing efficacy. Megan advises emerging entrepreneurs and innovators to stay true to one's mission, persevere, and be adaptable to bring innovative solutions to market. She encourages learning from experiences, building strong relationships with partners and stakeholders, and committing to making a positive impact. By following these principles, anyone can turn their passion into a successful and sustainable social enterprise that drives meaningful change.
Written by Gaayathri Ganesh, Editorial Writer, CUBEC
Feel free to check out:
